Drug checking identifies counterfeit alprazolam tablets
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND Non-prescribed benzodiazepine use is increasing in North America, especially among youth. Owing to increasing demand, counterfeit benzodiazepine tablets are mass-produced in clandestine, unregulated environments and sold as legitimate pharmaceuticals. This study aimed to examine the contents of counterfeit alprazolam tablets available in the unregulated drug market in British Columbia, Canada. METHODS Data were collected from an ongoing evaluation of a community drug checking service in British Columbia between October 2017 and March 2020. The service operates point-of-care in harm reduction sites using Fourier-transform infrared (FTIR) spectrometers coupled with fentanyl and benzodiazepine immunoassay strips. A subset of samples were sent for confirmatory analysis at partner laboratories and underwent one or more of gas chromatography/mass spectrometry, liquid chromatography/mass spectrometry, and quantitative nuclear magnetic resonance analysis. RESULTS During the study period, 10,814 total samples were submitted for drug checking, 139 of which were expected to be Xanax (alprazolam) or generic tablets and met the criteria for inclusion. Using FTIR analysis, 33 (23.7 %) samples were identified to contain alprazolam. Only 122 samples were checked using benzodiazepine immunoassay strips and 88 (72.1 %) tested positive. Qualitative results from the 20 samples submitted for confirmatory analysis included various new psychoactive substances and only 2 contained only alprazolam. CONCLUSIONS Our findings provide evidence that Xanax tablets obtained from the unregulated drug market are likely to be counterfeit and may not contain alprazolam. Drug checking offers people who use drugs a valuable means to determine the contents of their substances; however, limitations of point-of-care technologies must be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Benzodiazepine Use and Misuse Among Adults in the United States
Maust, D. T., Lin, L. A., & Blow, F. C. (2019) · Psychiatric Services · doi:10.1176/appi.ps.201800321 · Cited by 337
Tupper, K. W., McCrae, K., Garber, I., Lysyshyn, M., & Wood, E. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.06.020 · Cited by 238
Self-citationGreen, T. C., Park, J. N., Gilbert, M., McKenzie, M., Struth, E., Lucas, R., Clarke, W., & Sherman, S. G. (2020) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2020.102661 · Cited by 211
A Review of Alprazolam Use, Misuse, and Withdrawal
Ait-Daoud, N., Hamby, A. S., Sharma, S., & Blevins, D. (2018) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000350 · Cited by 195
Cited by
Drug checking services for people who use drugs: a systematic review
Maghsoudi, N., Tanguay, J., Scarfone, K., Rammohan, I., Ziegler, C., Werb, D., & Scheim, A. I. (2022) · Addiction · doi:10.1111/add.15734 · Cited by 261
Fentanyl Test Strips for Harm Reduction: A Scoping Review
Kutscher, E., Barber Grossi, M., LaPolla, F., & Lee, J. D. (2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001321 · Cited by 30
Zang, X., Bessey, S. E., Krieger, M. S., Hallowell, B. D., Koziol, J. A., Nolen, S., Behrends, C. N., Murphy, S. M., Walley, A. Y., Linas, B. P., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.41174 · Cited by 26
Metadata
- Authors
- Tobias, S., Shapiro, A. M., Grant, C. J., Patel, P., Lysyshyn, M., & Ti, L.
- Venue
- Drug and Alcohol Dependence
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 218
- Pages
- 108300
- ISSN
- 0376-8716 (ISSN-L)
- OpenAlex
- W3094236920
- Cited by
- 49
- References
- 4
- FWCI
- 12.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug checking identifies counterfeit alprazolam tablets. https://app.cochat.ai/papers/10.1016/j.drugalcdep.2020.108300
- The paper
- Tobias, S., Shapiro, A. M., Grant, C. J., Patel, P., Lysyshyn, M., & Ti, L. (2021). Drug checking identifies counterfeit alprazolam tablets. Drug and Alcohol Dependence. https://doi.org/10.1016/j.drugalcdep.2020.108300
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.